GlassScriptPhysician profile
Timothy E Mercer
NPI 1184668675
$4,906.83
in general payments reported to CMS, 2019-2025
22 companies · $1,889 in 2025
The $1,889 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $18.31 · 2024: $2,999 · 2025: $1,889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,620 · Education: $269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,619.59 |
| Education | $268.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,320.78 | 2024-2025 | Airsupra, Fasenra, Tezspire |
| Glaxosmithkline, LLC. | $843.59 | 2024-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Actelion Pharmaceuticals US, INC. | $360.22 | 2024-2025 | Opsumit, Uptravi, Opsynvi |
| Genzyme Corporation | $338.03 | 2024-2025 | |
| Electromed, INC. | $288.00 | 2024-2025 | Smartvest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $267.99 | 2024-2025 | Ofev, Jascayd |
| Regeneron Healthcare Solutions, INC. | $240.01 | 2024-2025 | Dupixent |
| Philips North America LLC | $187.15 | 2024 | (Ak6) Vest Therapy |
| Amgen INC. | $184.07 | 2024-2025 | Tezspire |
| Viatris Specialty LLC | $146.73 | 2025 | Yupelri |
| Paratek Pharmaceuticals, INC. | $119.52 | 2024 | Nuzyra |
| United Therapeutics Corporation | $118.92 | 2024-2025 | Tyvaso, Tyvaso |
| Verona Pharma, INC. | $107.27 | 2025 | Ohtuvayre |
| Sanofi-Aventis U.S. LLC | $99.95 | 2024 | |
| Pulmonx Corporation | $78.53 | 2025 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $61.48 | 2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $35.08 | 2024-2025 | Glassia |
| Astellas Pharma US INC | $29.94 | 2024 | Cresemba |
| Ambu INC. | $25.43 | 2024 | |
| Shionogi INC | $21.70 | 2025 | Fetroja |
| Genentech USA, INC. | $18.31 | 2021 | |
| Grifols USA, LLC | $14.13 | 2025 | Prolastin-C Liquid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Mercer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.